Table 1.
Baseline characteristics
| Characteristic | Value |
|---|---|
| Evaluable children, n(%) | 18 (100) |
| Median age, months (IQR) | 23.4 (12.1–27.8) |
| Age range | |
| 3–<12 months, n (%) | 4 (22) |
| 12–<24 months, n (%) | 6(33) |
| 24–<36 months, n (%) | 8 (44) |
| Gender | |
| Male, n (%) | 10(56) |
| Female, n (%) | 8 (44) |
| Median body weight, kg (IQR) | 11.3 (10.3–13.0) |
| Ethnic origin | |
| White, n (%) | 3 (17) |
| Black, n (%) | 14(78) |
| Mixed, n (%) | 1 (6) |
| CDC stage | |
| N, n (%) | 7 (39) |
| A, n (%) | 3(17) |
| B, n (%) | 1 (6) |
| C, n (%) | 7 (39) |
| Median cumulative ART exposure, months (IQR) | 11.3 (7.4–21.6) |
| Antiretroviral therapy combinationa | |
| 3TC+ABC+NVP (±AZT or ±d4T), n (%) | 10 (56) |
| 3TC+ABC+LPV/r (±AZT), n (%) | 7 (39) |
| FTC+ABC+LPV/r, n (%) | 1 (6) |
a
All children were taking all antiretroviral therapy (ART) drugs twice daily, with two exceptions: one child, who was on lamivudine (3TC) and abacavir (ABC), was taking nevirapine (NVP) once daily; and one child on abacavir (ABC) and lopinavir/ritonavir (LPV/r) was taking emtricitabine (FTC) once daily. The child evaluated for ABC only was 24–<36 months of age, female, 15.0 kg, White, CDC stage C and taking FTC, ABC plus LPV/r. AZT, zidovudine; d4T, stavudine; IQR, interquartile range.